Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
BglII: Mechanism and Evidence Boundaries
2026-10-14
APExBIO describes BglII restriction endonuclease (SKU K3010) as a genetically engineered, sequence-specific DNA-cleaving enzyme that recognizes 5′-AGATCT-3′ and produces cohesive DNA ends. The same product description reports rapid digestion, applicability to plasmid DNA, PCR products and genomic DNA, and tracer dyes for electrophoresis monitoring. Because no identity-matched research paper or independent performance dataset is available, these statements should be treated as supplier-level product information rather than validated comparative findings.
-
WecA as a Biochemical Antituberculosis Target
2026-10-14
A 2026 study establishes a biochemical framework for examining Mycobacterium tuberculosis WecA, a membrane-associated enzyme involved in cell-wall precursor synthesis. Its findings support WecA as a research target, but they do not demonstrate cellular efficacy, therapeutic potential, or relevance of Miransertib to WecA inhibition.
-
TP53, Iron Homeostasis and Ferroptosis in GBM
2026-10-13
A 2025 study links TP53 mutation status in glioblastoma models with altered iron handling, reduced ferritin heavy-chain abundance, and greater susceptibility to ferroptosis. The findings are preclinical and mechanistically informative, but they do not establish clinical efficacy, patient response, or the relevance of the separately listed CGK733 product.
-
What LMO2–LDB1 Reveals About AML Biology
2026-10-13
A source-grounded overview of a 2023 study linking the LMO2–LDB1 transcriptional complex to acute myeloid leukemia cell survival and proliferation, with attention to the study’s design, evidence strength, limitations, and its distinction from N6-Methyl-dATP research.
-
CF10–EdU Synergy and Telomere Attrition
2026-10-12
Das and colleagues examine why the fluoropyrimidine polymer CF10, but not 5-fluorouracil, synergizes strongly with EdU in colorectal cancer models. The reported findings connect enhanced EdU incorporation with DNA damage, cell-cycle disruption, reduced telomere staining and mitotic catastrophe, while remaining preclinical and mechanistically associative.
-
ATRNL1, Atrial Fibrillation, and Evidence Limits
2026-10-12
The cited study links ATRNL1 with cell-state and electrophysiological changes in atrial fibrillation through human left-atrial single-nucleus profiling and cell-model perturbation. It does not investigate IWR-1-endo, Wnt signaling, or a therapeutic application, so the findings should not be extended to Wnt inhibition or clinical treatment.
-
AZD6482 and the Evidence Gap in DM1 Biology
2026-10-10
AZD6482 is a selective PI3Kβ inhibitor with established biochemical, platelet, and metabolic research applications. This article explains why its pharmacology should not be conflated with the HSP90–p-STAT3–RNA foci mechanism reported in DM1, while defining scientifically defensible questions for future pathway studies.
-
HSP90 Regulation of RNA Foci in DM1
2026-10-09
Johnson and colleagues used an unbiased small-molecule RNA-FISH screen to identify HSP90 as a modifier of pathogenic DMPK RNA and CUG-repeat RNA foci in myotonic dystrophy type 1. The study further connects HSP90 to p-STAT3 in undifferentiated myoblasts while showing that differentiation reverses the response, emphasizing cell-state dependence and limits on therapeutic extrapolation.
-
Streptozotocin in Diabetes and Neuropathy Research
2026-10-09
A source-grounded overview of Streptozotocin (STZ) as a diabetes research model, including its reported β-cell effects, conceptual applications, links to painful diabetic neuropathy research, evidence strength, and translational limitations.
-
Flavopiridol and ER Stress in Intestinal Stem Cells
2026-10-08
Flavopiridol and L868275 are examined as mechanistic tools for interpreting ER-stress-related intestinal stem-cell injury, with emphasis on evidence boundaries, CDK biology, and translational relevance.
-
PGF2α/PTGFR Signaling in Endometrial Breakdown
2026-10-08
A 2024 mouse menstrual-like model study links PGF2α/PTGFR signaling to endometrial shedding, vascular permeability, and remodeling under HIF-1α regulation. Its integrated tissue, molecular, pharmacological, and human-cell evidence clarifies a mechanistic pathway while leaving important questions about human menstruation and wider FP-receptor biology unresolved.
-
Gaussia Luciferase mRNA for Lung LNP Research
2026-10-07
Gaussia Luciferase mRNA provides a biologically informative lens for evaluating RNA delivery, including emerging lung-targeted LNP systems. This article explains how m1Ψ-modified, capped reporter mRNA can support interpretation of delivery studies without confusing reporter expression with therapeutic benefit.
-
HSBP7 Rescue of Titin Cardiomyopathy
2026-10-07
A preprint introduces CARDIO, a high-content morphological profiling assay for human stem cell-derived cardiomyocytes, and applies it to CRISPR perturbation of genes associated with cardiac contractile function. The study identifies HSPB7 loss as a modifier that restores contractile performance in a titin-deficient model, while emphasizing that the finding remains preclinical and requires validation in more physiologically representative systems.
-
IWR-1-endo: A Cell-State Lens on Wnt Biology
2026-10-06
IWR-1-endo is a Wnt signaling inhibitor whose value extends beyond pathway suppression: it can help frame testable questions about cell state, β-catenin biology, and disease-associated transcriptional programs. This article connects its established colorectal cancer research applications with the cell-resolved evidence and interpretive limits of a major atrial fibrillation study.
-
MMP7, EMT, and Liver Fibrosis in Biliary Atresia
2026-10-05
A 2026 study identifies MMP7 as a mechanistic link between epithelial–mesenchymal transition and progressive liver fibrosis in biliary atresia. Its findings connect MMP7-mediated E-cadherin cleavage with β-catenin nuclear translocation and support MMP7 blockade as a disease-relevant antifibrotic concept, while leaving important translational questions unresolved.